Statins and cognitive decline in patients with Alzheimer's and mixed dementia: a longitudinal registry-based cohort study.

"Declarations Ethics approval and consent to participateThis study complies with the Declaration of Helsinki and was approved by the regional human ethics committee in Stockholm (numbers: 2015/743-31/4 and 2017/942-32). All patients and their relatives were informed of inclusion in SveDem at the time of diagnosis and had the right to decline the participation or withdraw the data from the registry at any point. The data were de-identified before analysis. Consent for publicationNot applicable. Competing interestsSGP holds stock in AstraZeneca, Bioarctic, Calliditas, Camurus, Dynavax, Moderna, Novo Nordisk, Pfizer, Sanofi, and Vicore. The other authors report no conflicts of interest. Competing interests SGP holds stock in AstraZeneca, Bioarctic, Calliditas, Camurus, Dynavax, Moderna, Novo Nordisk, Pfizer, Sanofi, and Vicore. The other authors report no conflicts of interest."

"Funding Open access funding provided by Karolinska Institute. This study was supported by the regional agreement on medical training and clinical research between the Stockholm Region and the Karolinska Institutet (ALF); the Health, Medicine and Technique grants from the Stockholm Region and Kungliga Tekniska Högskolan-KTH; Swedish medical research council grant (VR) # 2022-01425 (Garcia-Ptacek) and 2020-02014 (Eriksdotter); Stiftelsen Dementia; Margaretha af Ugglas Foundation; Karolinska Institutet Research Foundation; Karolinska Institutet Foundation for Diseases of Aging; Johanniterorden i Sverige/Swedish Order of St John; the Erling Persson foundation; and by the private initiative "Innovative ways to fight Alzheimer´s disease - Leif Lundblad Family and others"."